Ser37

Site Information
MCRLDIDsPPItARN SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 476070
Associated spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	2D analysis ( 14 ) , flow cytometry ( 10 ) , immunoassay ( 29 ) , immunoprecipitation ( 3 , 6 , 10 , 29 ) , mass spectrometry ( 2 , 3 , 4 , 6 , 7 , 9 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 27 , 28 , 30 , 31 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 ) , mutation of modification site ( 3 , 6 , 10 , 14 , 29 ) , phospho-antibody ( 3 , 5 , 6 , 10 , 14 , 29 ) , western blotting ( 3 , 5 , 6 , 10 , 14 , 29 )
Disease tissue studied:	bone cancer ( 45 ) , osteosarcoma ( 45 ) , brain cancer ( 10 , 29 , 36 ) , astrocytoma ( 36 ) , glioblastoma ( 10 , 29 ) , glioma ( 10 , 29 ) , breast cancer ( 3 , 9 , 14 , 17 , 18 , 30 ) , breast ductal carcinoma ( 17 ) , HER2 positive breast cancer ( 7 ) , luminal A breast cancer ( 7 ) , luminal B breast cancer ( 7 ) , breast cancer, surrounding tissue ( 7 ) , breast cancer, triple negative ( 7 , 17 ) , cervical cancer ( 46 ) , cervical adenocarcinoma ( 46 ) , colorectal cancer ( 5 ) , colorectal carcinoma ( 5 ) , leukemia ( 33 , 60 ) , acute myelogenous leukemia ( 33 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 28 ) , acute megakaryoblastic leukemia (M7) ( 28 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 28 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 28 ) , acute myeloblastic leukemia, without maturation (M1) ( 28 ) , chronic myelogenous leukemia ( 60 ) , lung cancer ( 6 , 15 , 23 , 30 , 39 , 51 , 56 ) , non-small cell lung cancer ( 6 , 30 , 51 , 56 ) , non-small cell lung adenocarcinoma ( 15 , 23 , 51 ) , lymphoma ( 19 ) , B cell lymphoma ( 28 ) , Burkitt's lymphoma ( 19 ) , non-Hodgkin's lymphoma ( 28 ) , follicular lymphoma ( 19 ) , mantle cell lymphoma ( 19 ) , ovarian cancer ( 17 ) , pancreatic ductal adenocarcinoma ( 22 ) , multiple myeloma ( 28 , 44 ) , melanoma skin cancer ( 13 )
Relevant cell line - cell type - tissue:	'muscle, skeletal' ( 34 , 48 ) , 'pancreatic, ductal'-pancreas ( 22 ) , 'stem, embryonic' ( 50 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 41 ) , 293 (epithelial) ( 52 ) , 293E (epithelial) ( 35 ) , 786-O (renal) [VHL (human), transfection] ( 11 ) , A498 (renal) ( 42 ) , A549 (pulmonary) ( 24 ) , AML-193 (monocyte) ( 28 ) , B lymphocyte-blood ( 44 ) , BJAB (B lymphocyte) ( 19 ) , breast ( 7 , 17 ) , BT-20 (breast cell) ( 30 ) , BT-474 (breast cell) ( 9 , 14 ) , BT-549 (breast cell) ( 30 ) , Calu 6 (pulmonary) ( 30 ) , CL1-0 (pulmonary) ( 39 ) , CL1-1 (pulmonary) ( 39 ) , CL1-2 (pulmonary) ( 39 ) , CL1-5 (pulmonary) ( 39 ) , CMK (megakaryoblast) ( 28 ) , CTS (myeloid) ( 28 ) , DG75 (B lymphocyte) ( 40 ) , DOHH2 ('B lymphocyte, precursor') ( 28 ) , FL-18 (B lymphocyte) ( 19 ) , FL-318 (B lymphocyte) ( 19 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 31 ) , Flp-In T-Rex-293 (epithelial) ( 31 ) , H2009 (pulmonary) ( 30 ) , H2077 (pulmonary) ( 30 ) , H2887 (pulmonary) ( 30 ) , H322M (pulmonary) ( 30 ) , HCC1359 (pulmonary) ( 30 ) , HCC1937 (breast cell) ( 30 ) , HCC2279 (pulmonary) ( 30 ) , HCC366 (pulmonary) ( 30 ) , HCC4006 (pulmonary) ( 30 ) , HCC78 (pulmonary) ( 30 ) , HCC827 (pulmonary) ( 30 ) , HCT116 (intestinal) ( 53 ) , HEK293T (epithelial) ( 3 , 12 , 66 ) , HEL (erythroid) ( 28 ) , HeLa (cervical) ( 4 , 16 , 27 , 38 , 47 , 53 , 58 , 61 , 64 , 67 ) , HeLa S3 (cervical) ( 46 , 57 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 18 ) , HMLER ('stem, breast cancer') ( 18 ) , HOP62 (pulmonary) ( 30 ) , HUES-7 ('stem, embryonic') ( 49 ) , HUES-9 ('stem, embryonic') ( 37 ) , JEKO-1 (B lymphocyte) ( 19 ) , Jurkat (T lymphocyte) ( 25 , 43 , 55 , 62 , 65 ) , K562 (erythroid) ( 27 , 47 , 60 ) , Kasumi-1 (myeloid) ( 28 ) , KG-1 (myeloid) ( 28 , 33 ) , LCLC-103H (pulmonary) ( 30 ) , liver ( 21 ) , LOU-NH91 (squamous) ( 30 ) , LoVo (intestinal) ( 5 ) , lung ( 23 ) , lymphocyte-blood ( 3 ) , MCF-10A (breast cell) ( 3 ) , MCF-7 (breast cell) ( 3 , 9 , 30 ) , MDA-MB-231 (breast cell) ( 14 , 30 ) , MDA-MB-468 (breast cell) ( 30 ) , MV4-11 (macrophage) ( 28 ) , NCEB-1 (B lymphocyte) ( 19 ) , NCI-H1299 (pulmonary) ( 6 , 56 ) , NCI-H1395 (pulmonary) ( 30 ) , NCI-H1568 (pulmonary) ( 30 ) , NCI-H157 (pulmonary) ( 30 ) , NCI-H1648 (pulmonary) ( 30 ) , NCI-H1666 (pulmonary) ( 30 ) , NCI-H1975 (pulmonary) ( 51 ) , NCI-H2030 (pulmonary) ( 30 ) , NCI-H2172 (pulmonary) ( 30 ) , NCI-H322 (pulmonary) ( 30 ) , NCI-H460 (pulmonary) ( 30 , 53 ) , NCI-H520 (squamous) ( 30 ) , NCI-H647 (pulmonary) ( 30 ) , OCI-ly1 (B lymphocyte) ( 19 ) , OPM-2 (plasma cell) ( 28 ) , ovary ( 17 ) , P31/FUJ (erythroid) ( 28 ) , PC9 (pulmonary) ( 30 ) , PC9-IR (pulmonary) ( 15 ) , platelet-blood ( 63 ) , Raji (B lymphocyte) ( 19 ) , RAMOS (B lymphocyte) ( 19 ) , REC-1 (B lymphocyte) ( 19 ) , RL ('B lymphocyte, precursor') ( 28 ) , RPMI-8266 (plasma cell) ( 28 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 20 ) , SH-SY5Y (neural crest) ( 20 ) , SU-DHL-4 (B lymphocyte) ( 19 ) , SU-DHL-6 (B lymphocyte) ( 28 ) , SW480 (intestinal) ( 5 ) , TERT20 ('stem, mesenchymal') ( 59 ) , U-118MG (glial) ( 36 ) , U266 (plasma cell) ( 28 ) , U2OS (bone cell) ( 45 ) , U87MG (glial) ( 10 , 29 ) , UPN-1 (B lymphocyte) ( 19 ) , Vero E6-S ('epithelial, kidney') ( 2 ) , WM115 (melanocyte) ( 54 ) , WM239A (melanocyte) ( 13 )

Upstream Regulation
Regulatory protein:	ECM1 (human) ( 14 )
Putative in vivo kinases:	ERK1 (human) ( 14 ) , ERK2 (human) ( 29 )
Kinases, in vitro:	Akt1 (human) ( 6 ) , ERK2 (human) ( 29 )
Putative upstream phosphatases:	CDC25A (human) ( 10 )
Treatments:	ascorbic_acid ( 5 ) , EGF ( 3 , 10 , 14 , 29 ) , metastatic potential ( 39 ) , nocodazole ( 46 ) , PUGNAc ( 3 ) , U0126 ( 14 , 29 )

Downstream Regulation
Effects of modification on PKM:	activity, induced ( 14 ) , intracellular localization ( 3 , 5 , 14 , 29 ) , molecular association, regulation ( 3 , 10 , 29 ) , phosphorylation ( 3 )
Effects of modification on biological processes:	carcinogenesis, induced ( 10 , 29 ) , cell growth, induced ( 10 ) , transcription, induced ( 5 , 29 ) , transcription, inhibited ( 10 )
Induce interaction with:	ERK1 (human) ( 3 ) , ERK2 (human) ( 3 ) , PIN1 (mouse) ( 29 )
Inhibit interaction with:	CTNNB1 (human) ( 10 )

Disease / Diagnostics Relevance
Relevant diseases:	glioblastoma multiforme ( 29 )

References
1	Nandi S, Razzaghi M, Srivastava D, Dey M (2020) Structural basis for allosteric regulation of pyruvate kinase M2 by phosphorylation and acetylation. J Biol Chem 32989054 Curated Info
2	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 32645325 Curated Info
3	Wang Y, et al. (2017) O-GlcNAcylation destabilizes the active tetrameric PKM2 to promote the Warburg effect. Proc Natl Acad Sci U S A 114, 13732-13737 29229835 Curated Info
4	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
5	Aguilera O, et al. (2016) Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer. Oncotarget 7, 47954-47965 27323830 Curated Info
6	Park YS, et al. (2016) AKT-induced PKM2 phosphorylation signals for IGF-1-stimulated cancer cell growth. Oncotarget 7, 48155-48167 27340866 Curated Info
7	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
8	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
9	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
10	Liang J, et al. (2016) PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis. Nat Commun 7, 12431 27485204 Curated Info
11	Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72 26506913 Curated Info
12	Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23 25278378 Curated Info
13	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
14	Lee KM, et al. (2015) ECM1 promotes the Warburg effect through EGF-mediated activation of PKM2. Cell Signal 27, 228-35 25446258 Curated Info
15	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
16	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
17	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
18	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
19	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
20	Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76 24117733 Curated Info
21	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
22	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
23	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
24	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
25	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
26	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
27	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
28	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
29	Yang W, et al. (2012) ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol 14, 1295-304 23178880 Curated Info
30	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
31	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
32	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
33	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
34	Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876 22673903 Curated Info
35	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
36	Possemato A (2011) CST Curation Set: 11927; Year: 2011; Biosample/Treatment: cell line, U118 MG/untreated; Disease: astrocytoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
37	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
38	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
39	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
40	Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72 20562096 Curated Info
41	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
42	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
43	Possemato A (2010) CST Curation Set: 9647; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V) Curated Info
44	Ge F, et al. (2010) Phosphoproteomic analysis of primary human multiple myeloma cells. J Proteomics 73, 1381-90 20230923 Curated Info
45	Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32 20058876 Curated Info
46	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
47	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
48	Højlund K, et al. (2009) In vivo phosphoproteome of human skeletal muscle revealed by phosphopeptide enrichment and HPLC-ESI-MS/MS. J Proteome Res 8, 4954-65 19764811 Curated Info
49	Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26 19664995 Curated Info
50	Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13 19664994 Curated Info
51	Moritz A (2009) CST Curation Set: 7293; Year: 2009; Biosample/Treatment: cell line, NCI-H1975/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
52	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
53	Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74 19415658 Curated Info
54	Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31 19362540 Curated Info
55	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
56	Tsai CF, et al. (2008) Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J Proteome Res 7, 4058-69 18707149 Curated Info
57	Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48 18691976 Curated Info
58	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
59	Thingholm TE, et al. (2008) TiO2-Based Phosphoproteomic Analysis of the Plasma Membrane and the Effects of Phosphatase Inhibitor Treatment. J Proteome Res 7, 3304-3313 18578522 Curated Info
60	Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
61	McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80 18212344 Curated Info
62	Stokes M (2008) CST Curation Set: 3884; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
63	Zahedi RP, et al. (2008) Phosphoproteome of resting human platelets. J Proteome Res 7, 526-34 18088087 Curated Info
64	Imami K, et al. (2008) Automated Phosphoproteome Analysis for Cultured Cancer Cells by Two-Dimensional NanoLC-MS Using a Calcined Titania/C18 Biphasic Column. Anal Sci 24, 161-6 18187866 Curated Info
65	Possemato A (2007) CST Curation Set: 3481; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
66	Molina H, et al. (2007) Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 104, 2199-204 17287340 Curated Info
67	Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92 16964243 Curated Info